# Nektar Therapeutics: financial statements, quarterly

NKTR · Nasdaq · CIK 906709 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nktr.md) · [Financials](/companies/nktr/financials.md) · [Filings](/companies/nktr/filings.md) · [Insiders](/companies/nktr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nktr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [24.1](/filings/0000950170-24-123570.md) | [23.9 d](/filings/0000950170-25-039389.md) | [21.6](/filings/0000950170-25-067279.md) | [23.5](/filings/0000950170-25-105275.md) | [24.1](/filings/0001193125-25-270230.md) | [29.2 d](/filings/0001193125-26-104547.md) | [10.5](/filings/0001193125-26-212596.md) | [11.2](/filings/0001193125-26-349805.md) | [11.8](/filings/0001193125-25-270230.md) | [21.8 d](/filings/0001193125-26-104547.md) | [10.9](/filings/0001193125-26-212596.md) | [10.1](/filings/0001193125-26-349805.md) |
| Cost of revenue | $m | [12.4](/filings/0000950170-24-123570.md) | [7.3 d](/filings/0000950170-25-039389.md) | [8.5](/filings/0000950170-25-067279.md) | [9.7](/filings/0000950170-25-105275.md) | [4.4](/filings/0001193125-25-270230.md) | [8.0 d](/filings/0001193125-26-104547.md) | [0.0](/filings/0000950170-25-067279.md) | [0.0](/filings/0000950170-25-105275.md) | [0.0](/filings/0001193125-25-270230.md) | [0.0 d](/filings/0001193125-26-104547.md) | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [24.1](/filings/0000950170-24-123570.md) | [29.9 d](/filings/0000950170-25-039389.md) | [27.4](/filings/0000950170-25-067279.md) | [29.7](/filings/0000950170-25-105275.md) | [35.0](/filings/0001193125-25-270230.md) | [28.7 d](/filings/0001193125-26-104547.md) | [30.5](/filings/0001193125-26-212596.md) | [29.9](/filings/0001193125-26-349805.md) | [27.3](/filings/0001193125-25-270230.md) | [29.7 d](/filings/0001193125-26-104547.md) | [35.7](/filings/0001193125-26-212596.md) | [39.1](/filings/0001193125-26-349805.md) |
| Operating income | $m | [(44.9)](/filings/0000950170-24-123570.md) | [(33.5) d](/filings/0000950170-25-039389.md) | [(35.4)](/filings/0000950170-25-067279.md) | [(49.8)](/filings/0000950170-25-105275.md) | [(34.3)](/filings/0001193125-25-270230.md) | [14.3 d](/filings/0001193125-26-104547.md) | [(44.5)](/filings/0001193125-26-212596.md) | [(36.2)](/filings/0001193125-26-349805.md) | [(31.7)](/filings/0001193125-25-270230.md) | [(27.7) d](/filings/0001193125-26-104547.md) | [(39.1)](/filings/0001193125-26-212596.md) | [(42.3)](/filings/0001193125-26-349805.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.1)](/filings/0000950170-24-123570.md) | [(0.0) d](/filings/0000950170-25-039389.md) | [(0.0)](/filings/0000950170-25-067279.md) | [0.0](/filings/0000950170-25-105275.md) | [0.0](/filings/0001193125-25-270230.md) | [(0.3) d](/filings/0001193125-26-104547.md) | [0.1](/filings/0001193125-26-212596.md) | [(0.2)](/filings/0001193125-26-349805.md) | [(0.0)](/filings/0001193125-25-270230.md) | [0.0 d](/filings/0001193125-26-104547.md) | [0.1](/filings/0001193125-26-212596.md) | [0.0](/filings/0001193125-26-349805.md) |
| Net income | $m | [(45.8)](/filings/0000950170-24-123570.md) | [(42.1) d](/filings/0000950170-25-039389.md) | [(36.8)](/filings/0000950170-25-067279.md) | [(52.4)](/filings/0000950170-25-105275.md) | [(37.1)](/filings/0001193125-25-270230.md) | [7.3 d](/filings/0001193125-26-104547.md) | [(50.9)](/filings/0001193125-26-212596.md) | [(41.6)](/filings/0001193125-26-349805.md) | [(35.5)](/filings/0001193125-25-270230.md) | [(36.1) d](/filings/0001193125-26-104547.md) | [(44.9)](/filings/0001193125-26-212596.md) | [(40.6)](/filings/0001193125-26-349805.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0000950170-24-123570.md) | not reported | [(0.19)](/filings/0000950170-25-067279.md) | [(3.76)](/filings/0000950170-25-105275.md) | [(2.66)](/filings/0001193125-25-270230.md) | not reported | [(3.62)](/filings/0001193125-26-212596.md) | [(2.95)](/filings/0001193125-26-349805.md) | [(1.87)](/filings/0001193125-25-270230.md) | not reported | [(1.82)](/filings/0001193125-26-212596.md) | [(1.23)](/filings/0001193125-26-349805.md) |
| Basic EPS | $ per share | [(0.24)](/filings/0000950170-24-123570.md) | not reported | [(0.19)](/filings/0000950170-25-067279.md) | [(3.76)](/filings/0000950170-25-105275.md) | [(2.66)](/filings/0001193125-25-270230.md) | not reported | [(3.62)](/filings/0001193125-26-212596.md) | [(2.95)](/filings/0001193125-26-349805.md) | [(1.87)](/filings/0001193125-25-270230.md) | not reported | [(1.82)](/filings/0001193125-26-212596.md) | [(1.23)](/filings/0001193125-26-349805.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [64.9](/filings/0000950170-23-060475.md) | [35.3](/filings/0000950170-25-039389.md) | [48.6](/filings/0000950170-24-057312.md) | [27.9](/filings/0000950170-24-094231.md) | [30.1](/filings/0000950170-24-123570.md) | [44.3](/filings/0001193125-26-104547.md) | [38.9](/filings/0000950170-25-067279.md) | [43.0](/filings/0000950170-25-105275.md) | [41.0](/filings/0001193125-25-270230.md) | [15.1](/filings/0001193125-26-349805.md) | [150](/filings/0001193125-26-212596.md) | [39.3](/filings/0001193125-26-349805.md) |
| Current assets | $m | [399](/filings/0000950170-23-060475.md) | [331](/filings/0000950170-25-039389.md) | [320](/filings/0000950170-24-057312.md) | [295](/filings/0000950170-24-094231.md) | [286](/filings/0000950170-24-123570.md) | [261](/filings/0001193125-26-104547.md) | [230](/filings/0000950170-25-067279.md) | [187](/filings/0000950170-25-105275.md) | [281](/filings/0001193125-25-270230.md) | [266](/filings/0001193125-26-349805.md) | [589](/filings/0001193125-26-212596.md) | [739](/filings/0001193125-26-349805.md) |
| Total assets | $m | [442](/filings/0000950170-23-060475.md) | [398](/filings/0000950170-25-039389.md) | [396](/filings/0000950170-24-057312.md) | [343](/filings/0000950170-24-094231.md) | [308](/filings/0000950170-24-123570.md) | [304](/filings/0001193125-26-104547.md) | [256](/filings/0000950170-25-067279.md) | [208](/filings/0000950170-25-105275.md) | [301](/filings/0001193125-25-270230.md) | [280](/filings/0001193125-26-349805.md) | [763](/filings/0001193125-26-212596.md) | [1,095](/filings/0001193125-26-349805.md) |
| Current liabilities | $m | [52.1](/filings/0000950170-23-060475.md) | [51.3](/filings/0000950170-25-039389.md) | [52.4](/filings/0000950170-24-057312.md) | [57.3](/filings/0000950170-24-094231.md) | [67.6](/filings/0000950170-24-123570.md) | [61.4](/filings/0001193125-26-104547.md) | [70.9](/filings/0000950170-25-067279.md) | [71.4](/filings/0000950170-25-105275.md) | [66.3](/filings/0001193125-25-270230.md) | [53.5](/filings/0001193125-26-349805.md) | [57.7](/filings/0001193125-26-212596.md) | [71.0](/filings/0001193125-26-349805.md) |
| Total liabilities | $m | [283](/filings/0000950170-23-060475.md) | [267](/filings/0000950170-25-039389.md) | [269](/filings/0000950170-24-057312.md) | [264](/filings/0000950170-24-094231.md) | [259](/filings/0000950170-24-123570.md) | [243](/filings/0001193125-26-104547.md) | [243](/filings/0000950170-25-067279.md) | [232](/filings/0000950170-25-105275.md) | [216](/filings/0001193125-25-270230.md) | [191](/filings/0001193125-26-349805.md) | [187](/filings/0001193125-26-212596.md) | [192](/filings/0001193125-26-349805.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [159](/filings/0000950170-24-123570.md) | [131](/filings/0001193125-26-104547.md) | [127](/filings/0001193125-25-270230.md) | [79.7](/filings/0001193125-25-270230.md) | [48.9](/filings/0001193125-25-270230.md) | [60.7](/filings/0001193125-26-349805.md) | [13.7](/filings/0001193125-26-349805.md) | [(24.2)](/filings/0001193125-26-349805.md) | [85.1](/filings/0001193125-25-270230.md) | [89.8](/filings/0001193125-26-349805.md) | [576](/filings/0001193125-26-349805.md) | [903](/filings/0001193125-26-349805.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(42.1) d](/filings/0000950170-24-123570.md) | [(47.0) d](/filings/0000950170-25-039389.md) | [(47.9)](/filings/0000950170-25-067279.md) | [(37.7) d](/filings/0000950170-25-105275.md) | [(43.9) d](/filings/0001193125-25-270230.md) | [(46.2) d](/filings/0001193125-26-104547.md) | [(49.1)](/filings/0001193125-26-212596.md) | [(45.7) d](/filings/0001193125-26-349805.md) | [(48.8) d](/filings/0001193125-25-270230.md) | [(65.0) d](/filings/0001193125-26-104547.md) | [(44.3)](/filings/0001193125-26-212596.md) | [(75.8) d](/filings/0001193125-26-349805.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-123570.md) | [0.2 d](/filings/0000950170-25-039389.md) | [0.2](/filings/0000950170-25-067279.md) | [0.2 d](/filings/0000950170-25-105275.md) | [0.7 d](/filings/0001193125-25-270230.md) | [0.5 d](/filings/0001193125-26-104547.md) | [0.0](/filings/0001193125-26-212596.md) | [0.0 d](/filings/0001193125-26-349805.md) | [0.1 d](/filings/0001193125-25-270230.md) | [0.0 d](/filings/0001193125-26-104547.md) | [0.0](/filings/0001193125-26-212596.md) | [0.1 d](/filings/0001193125-26-349805.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-123570.md) | [0.0 d](/filings/0000950170-25-039389.md) | [3.0](/filings/0000950170-25-067279.md) | [0.0 d](/filings/0000950170-25-105275.md) | [0.0 d](/filings/0001193125-25-270230.md) | [0.0 d](/filings/0001193125-26-104547.md) | [0.0](/filings/0000950170-25-067279.md) | [0.0 d](/filings/0000950170-25-105275.md) | [0.0 d](/filings/0001193125-25-270230.md) | [0.0 d](/filings/0001193125-26-104547.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [188](/filings/0000950170-23-060475.md) | [189](/filings/0000950170-24-057312.md) | [190](/filings/0000950170-24-094231.md) | [190](/filings/0000950170-24-123570.md) | [195](/filings/0000950170-25-067279.md) | [13.9](/filings/0000950170-25-105275.md) | [13.9](/filings/0001193125-25-270230.md) | [14.1](/filings/0001193125-26-212596.md) | [14.1](/filings/0001193125-26-349805.md) | [18.9](/filings/0001193125-25-270230.md) | [24.7](/filings/0001193125-26-212596.md) | [33.1](/filings/0001193125-26-349805.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 34,142,994 at 2026-08-07, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-349805.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.